(Q37866319)

24 August 2017

1 reference

title

Ritonavir-boosted protease inhibitors in HIV therapy (English)

1 reference

24 August 2017

0 references

1 reference

2

Julio S G Montaner

1 reference

24 August 2017

Mark W Hull

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

18 April 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

43

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

375-388

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Structure-Function Studies of HIV Reverse Transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Genetic locus, primary structure, and chemical synthesis of human immunodeficiency virus protease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Active human immunodeficiency virus protease is required for viral infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Structure-assisted design of nonpeptide human immunodeficiency virus-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Crystalluria and urinary tract abnormalities associated with indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Nelfinavir mesylate: a protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Low-dose ritonavir moderately enhances nelfinavir exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Lopinavir/ritonavir: a review of its use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Class-sparing regimens for initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

"Buffalo hump" in men with HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.572905

10.3109/07853890.2011.572905

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference